ImpediMed Taps Cancer Survivorship Leader to Expand SOZO’s Clinical Reach
Closing price · 2026-10-27: $0.004 · -11.11%
ImpediMed has appointed Dr Nicole Stout as Chief Clinical Innovation Officer, effective 1 November, to lead clinical strategy and support wider adoption of its SOZO platform in cancer care. The company says SOZO is established in lymphedema assessment, while recent FDA clearance for sarcopenia risk assessment enables the same scan to monitor muscle loss; the appointment is intended to help extend its use across cancer settings.